INO-1001 + temozolomide

INO-1001 + temozolomide is a **combination therapy** of INO-1001, a potent intravenous poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, and temozolomide, an oral alkylating agent used primarily as chemotherapy. **INO-1001 inhibits PARP-1 and PARP-2**, interfering with cellular DNA repair and thereby potentiating the cytotoxic effects of DNA-damaging agents such as temozolomide[1][6][8]. Temozolomide induces DNA methylation and damage, and the addition of INO-1001 impairs repair of these lesions by blocking PARP-mediated recovery, leading to enhanced tumor cell death[1][4][6]. The combination has been evaluated primarily in patients with unresectable stage III/IV melanoma, with clinical studies indicating modest efficacy and dose-limiting toxicities of myelosuppression and elevated liver transaminase at higher INO-1001 doses[1][2][6][8].

Brand names

Temodar

Other names

temozolomideInotek PARP inhibitor